RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains a Sector Perform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $85 to $80.
October 04, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Biomarin Pharmaceutical but has lowered the price target from $85 to $80, indicating a slightly less optimistic outlook.
The lowering of the price target from $85 to $80 by RBC Capital suggests a slightly less optimistic view on Biomarin's stock performance. This could lead to a short-term negative impact on the stock price as investors may adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100